Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, Hájek R, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Dimopoulos MA. Moreau P, et al. Among authors: facon t. Leukemia. 2017 Jan;31(1):115-122. doi: 10.1038/leu.2016.186. Epub 2016 Jul 4. Leukemia. 2017. PMID: 27491641 Free PMC article. Clinical Trial.
Double-intensive therapy in high-risk multiple myeloma.
Harousseau JL, Milpied N, Laporte JP, Collombat P, Facon T, Tigaud JD, Casassus P, Guilhot F, Ifrah N, Gandhour C. Harousseau JL, et al. Among authors: facon t. Blood. 1992 Jun 1;79(11):2827-33. Blood. 1992. PMID: 1350228 Free article.
Significance of circulating plasma cells in multiple myeloma.
Zandecki M, Facon T, Preudhomme C, Canis F, Izydorczyk V, Lovi V, Hammad M, Bauters F, Cosson A. Zandecki M, et al. Among authors: facon t. Leuk Lymphoma. 1994 Aug;14(5-6):491-6. doi: 10.3109/10428199409049709. Leuk Lymphoma. 1994. PMID: 7812210
Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
Moreau P, Fiere D, Bezwoda WR, Facon T, Attal M, Laporte JP, Colombat P, Haak HL, Monconduit M, Lockhorst H, Girault D, Harousseau JL. Moreau P, et al. Among authors: facon t. J Clin Oncol. 1997 Feb;15(2):660-6. doi: 10.1200/JCO.1997.15.2.660. J Clin Oncol. 1997. PMID: 9053491 Clinical Trial.
[Standard treatment of multiple myeloma].
Facon T. Facon T. Rev Med Interne. 1999 Jul;20(7):611-21. doi: 10.1016/s0248-8663(99)80112-x. Rev Med Interne. 1999. PMID: 10434353 Review. French.
Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.
Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Geneviève F, Zandecki M, Laï JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY; Intergroupe Francophone du Myélome. Facon T, et al. Blood. 2001 Mar 15;97(6):1566-71. doi: 10.1182/blood.v97.6.1566. Blood. 2001. PMID: 11238092 Free article.
Thalidomide in patients with advanced multiple myeloma.
Yakoub-Agha I, Moreau P, Leyvraz S, Berthou C, Payen C, Dumontet C, Grosbois B, Beris P, Duguet C, Attal M, Harousseau JL, Facon T; Intergroupe Francophone du Myélome (IFM). Yakoub-Agha I, et al. Among authors: facon t. Hematol J. 2000;1(3):186-9. doi: 10.1038/sj.thj.6200031. Hematol J. 2000. PMID: 11920188 Clinical Trial.
423 results